In the United States and the European Union, T‐DM1 is approved for use in patients with previously treated HER2‐positive metastatic breast cancer and in patients with HER2‐positive early breast cancer who have residual invasive disease following neoadjuvant treatment. The gene discussed is ERBB2; the disease is breast carcinoma.